HU183326B - Process for preparing new apovincaminol-3',4',5'-trimethoxy-benzoates substituted in the a ring and acid addition salts thereof - Google Patents
Process for preparing new apovincaminol-3',4',5'-trimethoxy-benzoates substituted in the a ring and acid addition salts thereof Download PDFInfo
- Publication number
- HU183326B HU183326B HU81324A HU32481A HU183326B HU 183326 B HU183326 B HU 183326B HU 81324 A HU81324 A HU 81324A HU 32481 A HU32481 A HU 32481A HU 183326 B HU183326 B HU 183326B
- Authority
- HU
- Hungary
- Prior art keywords
- acid addition
- apovincaminol
- formula
- bromo
- acid
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 26
- 239000002253 acid Substances 0.000 title claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 239000004480 active ingredient Substances 0.000 claims abstract description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 13
- SJSOFNCYXJUNBT-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1OC SJSOFNCYXJUNBT-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000001257 hydrogen Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims abstract description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 7
- IWPZKOJSYQZABD-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid Natural products COC1=CC(OC)=CC(C(O)=O)=C1 IWPZKOJSYQZABD-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- BUHYMJLFRZAFBF-UHFFFAOYSA-N 3,4,5-trimethoxybenzoyl chloride Chemical group COC1=CC(C(Cl)=O)=CC(OC)=C1OC BUHYMJLFRZAFBF-UHFFFAOYSA-N 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract description 9
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract description 9
- 201000004681 Psoriasis Diseases 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 7
- 230000004663 cell proliferation Effects 0.000 abstract description 6
- 208000017520 skin disease Diseases 0.000 abstract description 5
- 230000001575 pathological effect Effects 0.000 abstract description 4
- 238000005917 acylation reaction Methods 0.000 abstract description 3
- 230000010933 acylation Effects 0.000 abstract description 2
- 150000002431 hydrogen Chemical class 0.000 abstract description 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000006071 cream Substances 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 229950006936 apovincamine Drugs 0.000 description 10
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 9
- -1 tincture Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000000443 aerosol Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 238000002329 infrared spectrum Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 5
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229960001789 papaverine Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000005662 Paraffin oil Substances 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 150000004645 aluminates Chemical class 0.000 description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 3
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 3
- 229940098465 tincture Drugs 0.000 description 3
- 229960002117 triamcinolone acetonide Drugs 0.000 description 3
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HZNQSWJZTWOTKM-UHFFFAOYSA-N 2,3,4-trimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C(OC)=C1OC HZNQSWJZTWOTKM-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 238000006418 Brown reaction Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 241000786363 Rhampholeon spectrum Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QMSXPSURJTUZMP-UHFFFAOYSA-N Vincine Natural products COC1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 QMSXPSURJTUZMP-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical class COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960002726 vincamine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D461/00—Heterocyclic compounds containing indolo [3,2,1-d,e] pyrido [3,2,1,j] [1,5]-naphthyridine ring systems, e.g. vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Priority Applications (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU81324A HU183326B (en) | 1981-02-11 | 1981-02-11 | Process for preparing new apovincaminol-3',4',5'-trimethoxy-benzoates substituted in the a ring and acid addition salts thereof |
| AT0026282A AT382375B (de) | 1981-02-11 | 1982-01-26 | Verfahren zur herstellung von neuen, im ring a substituierten polycyclischen verbindungen und ihren saeureadditionssalzen |
| IL64876A IL64876A0 (en) | 1981-02-11 | 1982-01-27 | Vincamine compounds substituted on the a-ring,process for their preparation and pharmaceutical compositions containing them |
| SE8200524A SE8200524L (sv) | 1981-02-11 | 1982-01-29 | Polycykliska foreningar substituerade pa a-ringen, sett for deras framstellning och farmaceutiska beredningar innehallande dem |
| CA000395305A CA1199637A (en) | 1981-02-11 | 1982-02-01 | 10- and 11- substituted apovincaminol compounds and esters thereof with 3,4,5-trimetroxy benzoic and process for producing them |
| US06/345,633 US4432982A (en) | 1981-02-11 | 1982-02-04 | Polycyclic compounds substituted on the A-ring, pharmaceutical compositions containing them, and methods of treating psoriasis with them |
| FI820364A FI70019C (fi) | 1981-02-11 | 1982-02-04 | Analogifoerfarande foer framstaellning av terapeutiskt anvaendbara och isynnerhet vid behandling av psoriasis laempliga poycykliska foereningar och mellanprodukter som anvaends vi d oerfarandet |
| GR67243A GR75858B (en, 2012) | 1981-02-11 | 1982-02-08 | |
| ES509418A ES509418A0 (es) | 1981-02-11 | 1982-02-08 | Procedimiento de preparar trimetoxibenzoatos de apovincaminol substituidos con efecto inhibidor de las fosfodiestebasas. |
| NL8200493A NL8200493A (nl) | 1981-02-11 | 1982-02-09 | In de ring a gesubstitueerde polycyclische verbindingen, de zuuradditiezouten ervan, alsmede werkwijzen ter bereiding ervan. |
| BE0/207262A BE892070A (fr) | 1981-02-11 | 1982-02-09 | Composes polycycliques substitues sur le noyau a, procede pour leur preparation et compositions pharmaceutiques les contenant |
| FR8202046A FR2499573B1 (fr) | 1981-02-11 | 1982-02-09 | Composes polycycliques substitues sur le noyau a, procede pour leur preparation et compositions pharmaceutiques les contenant |
| PT74402A PT74402B (en) | 1981-02-11 | 1982-02-09 | Process for the preparation of new compounds of apovincaminol 3',4',5'-trimethoxy benzoate substituted on a ring and of phar-maceutical compositions containing them |
| NO820395A NO820395L (no) | 1981-02-11 | 1982-02-10 | Fremgangsmaate ved fremstilling av polycycliske forbindelser substituert paa a-ringen |
| JP57019012A JPS57150685A (en) | 1981-02-11 | 1982-02-10 | A ring-substituted polycyclic compound, manufacture and medicine containing same |
| AU80339/82A AU545745B2 (en) | 1981-02-11 | 1982-02-10 | Apovincaminol derivatives |
| DE19823204588 DE3204588A1 (de) | 1981-02-11 | 1982-02-10 | Im ring a substituierte apovincaminol-verbindungen, ihre saeureadditionssalze und verfahren zu ihrer herstellung |
| SU823388657A SU1069626A3 (ru) | 1981-02-11 | 1982-02-10 | Способ получени 3 @ ,4, @ 5 @ -триметоксиьензоата производных аповинкаминола или их солей |
| DK057682A DK151022C (da) | 1981-02-11 | 1982-02-10 | Analogifremgangsmaade til fremstilling af apovincaminol-3',4',5'-trimethoxybenzoatderivater og apovincaminolderivater til anvendelse ved fremgangsmaadenn |
| DD82237317A DD201593A5 (de) | 1981-02-11 | 1982-02-10 | Verfahren zur herstellung von im a-ring substituierten apovincaminol-3,4,5-trimethoxybenzoaten |
| IT19588/82A IT1157921B (it) | 1981-02-11 | 1982-02-10 | Composti policiclici sostituiti sull'anello a, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono |
| AR288400A AR228385A1 (es) | 1981-02-11 | 1982-02-11 | Procedimiento para la preparacion de nuevos compuestos policiclicos sustituidos en el ciclo a |
| GB8204017A GB2096597B (en) | 1981-02-11 | 1982-02-11 | Polycyclic compounds substituted on the a-ring process for their preparation and pharmaceutical compositions containing them |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU81324A HU183326B (en) | 1981-02-11 | 1981-02-11 | Process for preparing new apovincaminol-3',4',5'-trimethoxy-benzoates substituted in the a ring and acid addition salts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HU183326B true HU183326B (en) | 1984-04-28 |
Family
ID=10949091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU81324A HU183326B (en) | 1981-02-11 | 1981-02-11 | Process for preparing new apovincaminol-3',4',5'-trimethoxy-benzoates substituted in the a ring and acid addition salts thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US4432982A (en, 2012) |
| JP (1) | JPS57150685A (en, 2012) |
| AR (1) | AR228385A1 (en, 2012) |
| AT (1) | AT382375B (en, 2012) |
| AU (1) | AU545745B2 (en, 2012) |
| BE (1) | BE892070A (en, 2012) |
| CA (1) | CA1199637A (en, 2012) |
| DD (1) | DD201593A5 (en, 2012) |
| DE (1) | DE3204588A1 (en, 2012) |
| DK (1) | DK151022C (en, 2012) |
| ES (1) | ES509418A0 (en, 2012) |
| FI (1) | FI70019C (en, 2012) |
| FR (1) | FR2499573B1 (en, 2012) |
| GB (1) | GB2096597B (en, 2012) |
| GR (1) | GR75858B (en, 2012) |
| HU (1) | HU183326B (en, 2012) |
| IT (1) | IT1157921B (en, 2012) |
| NL (1) | NL8200493A (en, 2012) |
| NO (1) | NO820395L (en, 2012) |
| PT (1) | PT74402B (en, 2012) |
| SE (1) | SE8200524L (en, 2012) |
| SU (1) | SU1069626A3 (en, 2012) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU192013B (en) * | 1984-04-25 | 1987-04-28 | Richter Gedeon Vegyeszet | Process for production of new aporincavinol esther derivatives |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2035784A1 (en) * | 1969-03-27 | 1970-12-24 | Olivier Louisette | Vincamine derivs with therapeutic propert- - ies |
| DK139358B (da) * | 1973-12-18 | 1979-02-05 | Sandoz Ag | Analogifremgangsmåde til fremstilling af vincaminderivater eller syreadditionssalte deraf. |
| US4146643A (en) * | 1973-12-18 | 1979-03-27 | Sandoz Ltd. | Increasing vigilance or treating cerebral insufficiency with substituted vincamines |
| US4123535A (en) * | 1974-09-06 | 1978-10-31 | Sandoz Ltd. | Psychostimulating 14-amino-14,15-dihydroeburnamenines |
| HU170888B (hu) * | 1975-06-10 | 1977-09-28 | Richter Gedeon Vegyeszet | Sposob poluchenija novykh, opticheski aktivnykh proizvodnykh eburnameninov |
| HU177370B (en) * | 1977-07-27 | 1981-09-28 | Richter Gedeon Vegyeszet | Process for producing new bracket-cross-bracket-vincaminol-esters |
| IL60613A (en) * | 1979-08-16 | 1983-12-30 | Richter Gedeon Vegyeszet | Dermatological compositions applicable directly to the skin comprising an eburnamenine derivative and process for their preparation |
-
1981
- 1981-02-11 HU HU81324A patent/HU183326B/hu not_active IP Right Cessation
-
1982
- 1982-01-26 AT AT0026282A patent/AT382375B/de not_active IP Right Cessation
- 1982-01-29 SE SE8200524A patent/SE8200524L/xx not_active Application Discontinuation
- 1982-02-01 CA CA000395305A patent/CA1199637A/en not_active Expired
- 1982-02-04 US US06/345,633 patent/US4432982A/en not_active Expired - Fee Related
- 1982-02-04 FI FI820364A patent/FI70019C/fi not_active IP Right Cessation
- 1982-02-08 GR GR67243A patent/GR75858B/el unknown
- 1982-02-08 ES ES509418A patent/ES509418A0/es active Granted
- 1982-02-09 NL NL8200493A patent/NL8200493A/nl not_active Application Discontinuation
- 1982-02-09 FR FR8202046A patent/FR2499573B1/fr not_active Expired
- 1982-02-09 PT PT74402A patent/PT74402B/pt unknown
- 1982-02-09 BE BE0/207262A patent/BE892070A/fr not_active IP Right Cessation
- 1982-02-10 NO NO820395A patent/NO820395L/no unknown
- 1982-02-10 IT IT19588/82A patent/IT1157921B/it active
- 1982-02-10 SU SU823388657A patent/SU1069626A3/ru active
- 1982-02-10 DE DE19823204588 patent/DE3204588A1/de active Granted
- 1982-02-10 AU AU80339/82A patent/AU545745B2/en not_active Ceased
- 1982-02-10 JP JP57019012A patent/JPS57150685A/ja active Granted
- 1982-02-10 DK DK057682A patent/DK151022C/da not_active IP Right Cessation
- 1982-02-10 DD DD82237317A patent/DD201593A5/de not_active IP Right Cessation
- 1982-02-11 AR AR288400A patent/AR228385A1/es active
- 1982-02-11 GB GB8204017A patent/GB2096597B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| PT74402A (en) | 1982-03-01 |
| DK151022B (da) | 1987-10-12 |
| DK151022C (da) | 1988-06-20 |
| SE8200524L (sv) | 1982-08-12 |
| JPH0378393B2 (en, 2012) | 1991-12-13 |
| GB2096597B (en) | 1984-10-24 |
| ES8307803A1 (es) | 1983-08-01 |
| DD201593A5 (de) | 1983-07-27 |
| GB2096597A (en) | 1982-10-20 |
| IT1157921B (it) | 1987-02-18 |
| NO820395L (no) | 1982-08-12 |
| NL8200493A (nl) | 1982-09-01 |
| FR2499573B1 (fr) | 1985-12-27 |
| DE3204588A1 (de) | 1982-12-30 |
| AU545745B2 (en) | 1985-08-01 |
| FI820364L (fi) | 1982-08-12 |
| DK57682A (da) | 1982-08-12 |
| SU1069626A3 (ru) | 1984-01-23 |
| CA1199637A (en) | 1986-01-21 |
| JPS57150685A (en) | 1982-09-17 |
| BE892070A (fr) | 1982-08-09 |
| ES509418A0 (es) | 1983-08-01 |
| GR75858B (en, 2012) | 1984-08-02 |
| DE3204588C2 (en, 2012) | 1990-10-04 |
| PT74402B (en) | 1983-07-07 |
| FI70019C (fi) | 1986-09-12 |
| AT382375B (de) | 1987-02-25 |
| US4432982A (en) | 1984-02-21 |
| FR2499573A1 (fr) | 1982-08-13 |
| FI70019B (fi) | 1986-01-31 |
| AR228385A1 (es) | 1983-02-28 |
| IT8219588A0 (it) | 1982-02-10 |
| AU8033982A (en) | 1982-08-19 |
| ATA26282A (de) | 1986-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH645642A5 (fr) | Derives de d-6-n-propylergolines, leur procede de preparation et compositions pharmaceutiques en contenant. | |
| HU183326B (en) | Process for preparing new apovincaminol-3',4',5'-trimethoxy-benzoates substituted in the a ring and acid addition salts thereof | |
| US4424223A (en) | Polycyclic compounds containing a double bond in the D-ring pharmaceutical compositions containing them, and methods of treating psoriasis with them | |
| US4419359A (en) | Nitro-substituted polycyclic derivatives useful in the treatment of psoriasis | |
| US4680397A (en) | Apovincaminol derivative | |
| CA1202028A (en) | Apovincaminol-3',4',5'-trimethoxy-benzoate compounds | |
| US4424224A (en) | Apovincaminol derivative and compositions and methods utilizing it for treating psoriasis | |
| US5405868A (en) | 5-methoxy-psoralen as new medicament and process for the synthesis thereof | |
| CA1215061A (en) | 17-18-dehydro-apovincaminol and process therefor | |
| FR2548183A1 (fr) | Diphenylazomethines portant un radical imidazolyle, leur preparation et leur application en therapeutique | |
| CH650507A5 (en) | Apovincaminol derivatives, a process for their preparation and drugs containing these compounds | |
| EP0323303A1 (fr) | Dérivés de nicotinoyl-pipérazine, procédé de préparation et utilisation en thérapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HU90 | Patent valid on 900628 | ||
| HMM4 | Cancellation of final prot. due to non-payment of fee |